Substance P enhances the proliferation and migration potential of murine bone marrow‑derived mesenchymal stem cell‑like cell lines

Dubon,Maria  Jose; Park,Ki‑Sook

doi:10.3892/etm.2015.2291

Substance P enhances the proliferation and migration potential of murine bone marrow‑derived mesenchymal stem cell‑like cell lines

Authors:
- Maria Jose Dubon
- Ki‑Sook Park
View Affiliations

Affiliations: Graduate School of Biotechnology, Kyung Hee University, Yong‑In, Gyeonggi 466‑701, Republic of Korea, East‑West Medical Research Institute, Kyung Hee University, Seoul 130‑701, Republic of Korea
Published online on: February 13, 2015 https://doi.org/10.3892/etm.2015.2291
Pages: 1185-1191
Copyright: © Dubon et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Due to the therapeutic characteristics of bone marrow (BM)‑derived mesenchymal stem cells (MSCs), clinical trials are testing the use of autologous or allogeneic MSCs for the treatment of several conditions. These therapies require large numbers of MSCs and numerous studies are attempting to find substances that could enhance the egression of endogenous MSCs from the BM into the periphery and increase their proliferation in vivo and in vitro. It has been reported that substance P (SP) has the potential to increase the expansion of MSCs in vivo and to induce their mobilization from the BM into the periphery. The aim of the present study was to investigate the effects of SP on the migration and proliferation potential of two BM‑derived MSC‑like cell lines, ST2 and OP9. SP was found to induce the migration potential of ST2 cells in vitro. Furthermore, SP increased the proliferation of the MSCs cell line, OP9 cell line. Cyclin D1 expression was observed to increase in the OP9 cells, indicating the activation of the cell cycle in response to SP. The upstream signals involved in these phenomena have yet to be elucidated, although previous studies have proposed the activation of the extracellular signal‑regulated kinase‑1/2 and Wingless/β‑catenin pathways as possible mediators of the cellular proliferation of human MSCs in response to SP. The present results therefore suggest that SP would facilitate the obtainment of higher numbers of endogenous MSCs from patients or donors and/or shorten the process of in vitro expansion that could cause the MSCs to undergo changes in their innate therapeutic characteristics prior to their use in therapy.

View Figures

View References

1	Lotfinegad P, Shamsasenjan K, Movassaghpour A, Majidi J and Baradaran B: Immunomodulatory nature and site specific affinity of mesenchymal stem cells: A hope in cell therapy. Adv Pharm Bull. 4:5–13. 2014.PubMed/NCBI
2	Tang YL, Zhao Q, Zhang YC, et al: Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium. Regul Pept. 117:3–10. 2004. View Article : Google Scholar
3	Aggarwal S and Pittenger MF: Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 105:1815–1822. 2005. View Article : Google Scholar
4	Herrera MB, Bussolati B, Bruno S, Fonsato V, Romanazzi GM and Camussi G: Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med. 14:1035–1041. 2004.PubMed/NCBI
5	Shake JG, Gruber PJ, Baumgartner WA, et al: Mesenchymal stem cell implantation in a swine myocardial infarct model: Engraftment and functional effects. Ann Thorac Surg. 73:1919–1925. 2002. View Article : Google Scholar : PubMed/NCBI
6	Kim N and Cho SG: Clinical applications of mesenchymal stem cells. Korean J Intern Med. 28:387–402. 2013. View Article : Google Scholar : PubMed/NCBI
7	Banfi A, Muraglia A, Dozin B, Mastrogiacomo M, Cancedda R and Quarto R: Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: Implications for their use in cell therapy. Exp Hematol. 28:707–715. 2000. View Article : Google Scholar : PubMed/NCBI
8	Hong HS, Lee J, Lee E, et al: A new role of substance P as an injury-inducible messenger for mobilization of CD29(+) stromal-like cells. Nat Med. 15:425–435. 2009. View Article : Google Scholar : PubMed/NCBI
9	Dubon MJ, Byeon Y, Jung N, Son Y and Park KS: Substance P modulates properties of bone marrow-derived mesenchymal stem cells. Tissue Eng Regen Med. 11:217–223. 2014. View Article : Google Scholar
10	Ogawa M, Nishikawa S, Ikuta K, et al: B cell ontogeny in murine embryo studied by a culture system with the monolayer of a stromal cell clone, ST2: B cell progenitor develops first in the embryonal body rather than in the yolk sac. EMBO J. 7:1337–1343. 1988.PubMed/NCBI
11	Tong J, Kishi H, Matsuda T and Muraguchi A: A bone marrow-derived stroma cell line, ST2, can support the differentiation of fetal thymocytes from the CD4⁺ CD8⁺ double negative to the CD4⁺ CD8⁺ double positive differentiation stage in vitro. Immunology. 97:672–678. 1999. View Article : Google Scholar : PubMed/NCBI
12	Trentin JJ: Determination of bone marrow stem cell differentiation by stromal hemopoietic inductive microenvironments (HIM). Am J Pathol. 65:621–628. 1971.PubMed/NCBI
13	Mercier FE, Ragu C and Scadden DT: The bone marrow at the crossroads of blood and immunity. Nat Rev Immunol. 12:49–60. 2011. View Article : Google Scholar : PubMed/NCBI
14	Gao J, Yan XL, Li R, et al: Characterization of OP9 as authentic mesenchymal stem cell line. J Genet Genomics. 37:475–482. 2010. View Article : Google Scholar : PubMed/NCBI
15	Stacey DW: Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol. 15:158–163. 2003. View Article : Google Scholar : PubMed/NCBI
16	Bernardo ME, Cometa AM, Pagliara D, et al: Ex vivo expansion of mesenchymal stromal cells. Best Pract Res Clin Haematol. 24:73–81. 2011. View Article : Google Scholar : PubMed/NCBI
17	Fossett E and Khan WS: Optimising human mesenchymal stem cell numbers for clinical application: A literature review. Stem Cells Int. 2012:4652592012. View Article : Google Scholar : PubMed/NCBI
18	Bentivegna A, Miloso M, Riva G, et al: DNA methylation changes during in vitro propagation of human mesenchymal stem cells: Implications for their genomic stability? Stem Cells Int. 2013:1924252013. View Article : Google Scholar : PubMed/NCBI
19	Pelus LM: Peripheral blood stem cell mobilization: New regimens, new cells, where do we stand. Curr Opin Hematol. 15:285–292. 2008. View Article : Google Scholar : PubMed/NCBI
20	Offley SC, Guo TZ, Wei T, et al: Capsaicin-sensitive sensory neurons contribute to the maintenance of trabecular bone integrity. J Bone Miner Res. 20:257–267. 2005. View Article : Google Scholar : PubMed/NCBI
21	Deng J, Zou ZM, Zhou TL, et al: Bone marrow mesenchymal stem cells can be mobilized into peripheral blood by G-CSF in vivo and integrate into traumatically injured cerebral tissue. Neurol Sci. 32:641–651. 2011. View Article : Google Scholar : PubMed/NCBI
22	Pitchford SC, Furze RC, Jones CP, Wengner AM and Rankin SM: Differential mobilization of subsets of progenitor cells from the bone marrow. Cell Stem Cell. 4:62–72. 2009. View Article : Google Scholar : PubMed/NCBI
23	Hitomi M and Stacey DW: Cellular ras and cyclin D1 are required during different cell cycle periods in cycling NIH 3T3 cells. Mol Cell Biol. 19:4623–4632. 1999.PubMed/NCBI